Healio | May 17, 2024

Earlier this year, the FDA granted breakthrough device designation to Quanterix for its blood-based diagnostic assay to aid in the diagnosis of Alzheimer’s disease.

LucentAD p-Tau 217 is a semi-quantitative in vitro diagnostic immunoassay intended to measure phosphorylated-tau 217, a biomarker that may be crucial in diagnosing Alzheimer’s disease in those who present to a clinical setting with cognitive impairment. Read the full article.